皮肤癌诊断中人工智能的伦理问题:用例分析
该研究对英国两款流行的皮肤癌AI辅助智能手机应用(SkinVision和Scanoma)进行伦理用例分析,通过系统检索文献、监管文件和网站评估其开发、有效性和使用。研究发现两款应用在算法透明度、研究质量、肤色偏倚和监管方面存在伦理缺陷,生物伦理规范如公正、责任和透明度未被充分纳入。
要点
- 两款皮肤癌AI应用在算法开发透明度和研究质量上存在显著差异。
- 一款应用将深肤色人群排除在目标用户之外,可能加剧现有不平等。
- 监管不足,需加强问责并将伦理设计融入技术开发与部署。
核心结论
- 两款面向患者的皮肤癌AI辅助应用在开发和部署中未充分纳入公正、责任和透明度等生物伦理规范。
- 亟需改进监管以增加问责,并通过技术开发者、皮肤科医生、伦理学家和公众的协作确保伦理设计。
研究设计与样本
- 对英国两款流行的皮肤癌应用SkinVision和Scanoma进行伦理用例分析。
- 采用已建立的临床AI伦理分析方法,系统检索已发表文献、监管文件和网站,由两名研究者独立筛选纳入。
主要发现
- 一款公司提供了关于算法开发和决策的详细细节,另一款应用的信息报告不足。
- 评估算法有效性的研究在数量、质量和一致性方面存在担忧。
- 一款应用在解决潜在肤色偏倚方面努力有限,并将深肤色个体排除在目标用户之外,可能加剧现有不平等。
- 识别出监管监督不足。
临床怎么用
- 临床医生应了解皮肤癌AI应用在算法透明度、研究质量和肤色偏倚方面的伦理缺陷。
- 需推动改进监管以增加问责,并促进技术开发者、皮肤科医生、伦理学家和公众的协作。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Skin cancer is the most common cancer worldwide. Early diagnosis is crucial to improving patient survival and morbidity. Artificial intelligence (AI)-assisted smartphone applications (apps) for skin cancer potentially offer accessible, early risk assessment of suspicious skin lesions. However, the integration of novel technologies into dermatology pathways raises ethical concerns. Although ethical principles for AI governance are well known, how these principles should be applied to real-life AI apps readily available for public use is less well understood. OBJECTIVES: To conduct an ethical use-case analysis of commercially available skin cancer apps, to better understand the ethical issues arising from their development and use in a real-world context. METHODS: Established methods for the ethical analysis of clinical AI applications were applied to two popular skin cancer apps in the UK: SkinVision and Scanoma. Systematic searches of published literature, regulatory documents and websites were conducted to review the evidence regarding app development, effectiveness and use. Screening for inclusion was undertaken by two researchers independently. Ethical concerns were identified with reference to previously described ethical concerns and principles for AI-assisted healthcare. RESULTS: By conceptualizing ethical principles within the use-context of skin cancer apps, we identified specific ethical issues arising throughout the AI lifecycle of both apps. One company provided extensive detail regarding algorithm development and decision-making; this information was insufficiently reported for the other app. Other concerns identified were related to number, quality and consistency of studies assessing algorithm efficacy. Limited efforts to address potential skin tone biases and the exclusion of individuals with darker skin tones as target users by one app risks perpetuating existing inequalities. Inadequate regulatory oversight was identified. CONCLUSIONS: Findings from our ethical use-case analysis of two patient-facing AI-assisted skin cancer apps suggest inadequate incorporation of bioethical norms such as justice, responsibility and transparency into the development and deployment of both apps. Improved regulation should increase accountability. Ensuring ethics by design through integration between technology developers, dermatologists, ethicists and the public is urgently needed to prevent the potential benefits of AI-assisted skin cancer apps being overshadowed by potential ethical harms. Skin cancer is the most common cancer worldwide. Early diagnosis can help people live longer and fuller lives. Apps offer to check suspicious skin spots for signs of cancer by using artificial intelligence (or ‘AI’) to look at photographs of the skin. Using these apps in dermatology raises ethical questions. We aimed to better understand the ethical issues that arise when the public use AI-assisted skin cancer apps. We reviewed scientific articles, regulatory documents and online information for two popular skin cancer apps in the UK. We did this to understand how they were developed, how effective they are and how they are used. We identified specific issues related to the development and use of each app. We uncovered several ethical issues. One app provided detailed information about how it works and how it was developed. The other app did not. We found concerns about the quality of the studies assessing how effective the apps were. The app developers recognized that their apps may not be suitable for some people (for example, older people or people with darker skin tones). However, they did not properly address these biases, which could disadvantage certain people. We also identified some gaps in the way that these apps are regulated. Our research shows that the apps do not follow key ethical principles. We think better regulation and teamwork between app developers, skin doctors, ethics experts and the public can make AI skin cancer apps safer and more helpful for everyone.
引用
- Shah SFH, Arecco D, Draper H, et al. Ethical implications of artificial intelligence in skin cancer diagnostics: use-case analyses. Br J Dermatol. 2025. PMID: 39501748. doi:10.1093/bjd/ljae434
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。